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Abstract - Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS), a human 
inflammatory and demyelinating disease. Microglia and astrocytes are glial cells of the central nervous system (CNS) that 
play a dual role in MS and EAE pathology. The aim of this study was to examine the effect of combined treatment with two 
nucleoside analogues, ribavirin and tiazofurin, on microglia and astrocytes in actively induced EAE. Therapeutic treat-
ment with a combination of these two nucleoside analogues reduced disease severity, mononuclear cell infiltration and 
demyelination. The obtained histological results indicate that ribavirin and tiazofurin changed activated microglia into an 
inactive type and attenuated astrocyte reactivity at the end of the treatment period. Since reduction of reactive microglio-
sis and astrogliosis correlated with EAE suppression, the present study also suggests that the obtained beneficial effect of 
ribavirin and tiazofurin could be a consequence of their action inside as well as outside the CNS. 
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INTRODuCTION
Multiple sclerosis (MS) is a chronic demyelinating 
inflammatory disease of the human central nervous 
system (CNS) characterized by a variable degree of 
axonal loss that correlates with neurological disabili-
ty (Bjartmar et al., 2000). Experimental autoimmune 
encephalomyelitis (EAE) is an animal model of mul-
tiple sclerosis (MS) and a helpful tool in the preclini-
cal testing of various substances under consideration 
for treatment of this human disease of the CNS. 
Ribavirin  (RBV;  1-β-D-ribofuranosyl-1,2,4-
triazole-3-carbox-amide) and tiazofurin (TR; 2-β-D-
ribofuranosylthiasole-4-carboxamide) are synthetic 
nucleoside analogues that exert immunosuppressive 
action in EAE (Stosic-Grujicic et al., 2002; Lavrnja et 
al., 2008; Stojkov et al., 2008) through the inhibition 
of  inosine-monophosphate-dehydrogenase  (IMP-
DH), a rate-limiting enzyme in the de novo purine 
synthesis pathway.
A normal mature nervous system possesses resi-
dent immunocompetent cells, known as microglia. 
They persist as a resting ramified form that upon 
even minor disturbances in the CNS, become acti-
vated amoeboid cells. Once activated, microglia pro-
duce various proinflammatory factors (i.e. TNF-α, 
IL-1β, IL-6) (Smith et al., 2012), which alert nearby 
astroglial cells and trigger astrogliosis (Glass et al., 
2010). Reactive astrogliosis can play a detrimental 
role in MS and EAE, since reactive astrocytes may 
act as proinflammatory mediators (Nair et al., 2008). 
In addition, it has been shown that increased glial 844 DANIJELA SAVIĆ ET AL.
scarring, as a consequence of chronic disease activity 
in MS, is associated with an accumulating neurologi-
cal deficit (Raine, 1997).
Since our prior experiments were focused on the 
peripheral effects of RBV and TR in EAE, the present 
study  addressed  the  question  as  to  whether  CNS 
cells, microglia and astrocytes could be the potential 
targets in a RBV+TR combined therapy, adminis-
trated at the appearance of the first clinical signs of 
EAE. We carried out clinical, histopathological and 
immunohistochemical evaluations of EAE to reveal 
the effect of this drug cocktail on glial cells. 
MATERIALS AND METHODS
Animals and EAE induction
Male Dark Agouti (DA) rats (12 weeks old), were 
obtained from the Institute for Biological Research 
“Siniša Stanković” (Belgrade, Serbia). Three to five 
animals (200-250 g) were kept per cage. The rats were 
immunized as previously described in Stojkov et al. 
(2008). Animals were monitored daily for the clini-
cal signs EAE which were scored from 0 to 5 using 
the following scale: (0) no clinical signs; (1) flaccid 
tail; (2) hind limb paresis; (3) hind limb paralysis; (4) 
moribund state, (5) death. The following parameters 
of the disease were examined to evaluate the severity 
of EAE during the treatment period (15 days): mean 
clinical score (average clinical scores for all rats with-
in a group on a given treatment day); mean maximal 
severity score (the mean of the maximal clinical score 
that each rat in a group developed over the treatment 
period); duration of paralysis (the mean number of 
days during the treatment period for which the rats 
had a score of 3 or more). All animals were treated 
in accordance with the principles from the Guide for 
Care and use of Laboratory Animals, NIH Publica-
tion No. 80-23 and the protocols were approved by 
the Belgrade university Animal Care and use Com-
mittee. 
Treatment procedure
Ribavirin (RBV) and tiazofurin (TR) were provided 
by  ICN  Pharmaceuticals  (Costa  Mesa,  CA,  uSA). 
The rats were randomly divided at the beginning of 
the experiment into 2 groups: an EAE group (saline 
treated, 0.2 ml/kg/day of saline i.p.) and a RBV+TR 
group which was treated with a combination of the 
following dosages: 30 mg/kg/day (RBV) + 10 mg/
kg/every other day (TR). In all groups, each animal 
was treated individually, beginning from the appear-
ance of the first signs of EAE (from 7 to 11 days post 
immunization). The treatment period lasted for 15 
days. After cessation of treatment, the animals were 
killed under deep anesthesia, from day 21 to day 25, 
depending on the onset of the disease for each ani-
mal. The spinal cords were dissected and prepared 
for cryosectioning. 
Histochemistry and immunohistochemistry
Frozen transverse 16 μm-thick lumbar spinal cord 
sections  were  used  for  histological  and  immuno-
logical  analysis.  Histological  staining  with  Luxol 
Fast Blue (LFB)/Cresyl Violet (CV) was performed 
to detect demyelination and inflammatory infiltrates 
according to standard procedure. Immunolabeling 
was performed for anti-ED1 (Serotec, mouse, 1:400), 
anti-GFAP (DAKO, rabbit, 1:500) and anti-vimentin 
(DAKO, mouse, 1:200). Briefly, non-specific bind-
ing was reduced with 10% normal goat serum (for 
ED1 and vimentin) or 10% normal rabbit serum (for 
GFAP) in 0.01 M phosphate buffered saline pH 7.4. 
Primary antibodies were applied overnight at 4°C. 
Appropriate horseradish peroxidase conjugated sec-
ondary antibodies (Santa Cruz Biotechnology, Santa 
Cruz, CA, uSA) were used and the reaction prod-
uct was visualized with 3′3-diaminobenzidine (DAB, 
Dako) according to the manufacturer’s instructions. 
Negative control of labeling was performed by the 
omission of the primary antibody, and did not result 
in specific labeling. After dehydration and clearing, 
sections  were  mounted  with  DPX  Mounting  me-
dium (Fluka) and examined under a Zeiss Axiovert 
microscope.
Statistical Analysis
The results are expressed as means ± SEM. Signifi-NuCLEOSIDE ANALOGuES AND GLIOSIS 845
cance between the differences of the disease param-
eters: mean clinical score, mean maximal severity 
score and duration of paralysis, were evaluated by 
ANOVA. Significant differences were accepted at *P 
< 0.05 and **P < 0.001 vs. EAE-rats that were used 
as controls. 
RESuLTS
Clinical and general pathological features of  
EAE rats treated with RBV+TR
All immunized animals developed clinical signs of 
fig. 1. Clinical and pathological features of EAE. (A) The effect of RBV+TR treatment on the suppression of clinical signs of EAE over 
the treatment period (15 days). Results are means ± SEM. *P< 0.05, ** P<0.001 vs. EAE-rats that were used as controls. Detection of 
demyelination and inflammatory infiltrates in 16-µm-thick cryosections of the lumbar spinal cord by Luxol Fast Blue/Cresyl Violet 
staining in EAE rats (b, arrows) and RBV+TR treated rats (C). Gray matter (gm) and white matter (wm). Bar b-C: 100 µm. 846 DANIJELA SAVIĆ ET AL.
disease. In order to ensure that RBV+TR treatment 
was initiated at the beginning of the disease, the treat-
ment was applied individually, at the appearance of 
the first sign of EAE (flaccid tail), and lasted 15 days. 
RBV+TR-treated rats developed a noticeably milder 
form of EAE (Fig. 1A), as judged by several param-
eters of disease severity (Table 1). In the RBV+TR-
group, only 5 of 16 animals passed through paralysis, 
while 14 out of 16 animals from the EAE-group had 
this severe disease symptom. On cessation of treat-
ment, 15 out of 16 RBV+TR-treated rats completely 
recovered, and one animal exhibited paresis. In EAE-
untreated animals, at the end of treatment protocol, 
only 3 out of 16 rats completely recovered, 11 rats 
had flaccid tails and 2 displayed paresis. In addition, 
mortality was not registered in any of the groups.
LFB/CV staining of lumbar spinal cord sections 
revealed widespread demyelination that correlated 
with massive cellular infiltrates throughout the white 
matter columns and gray matter of EAE-rats (Fig. 
1B, arrows). In the RBV+TR-treated rats, demyelina-
tion plaques were not detected and the white matter, 
as well as the gray matter of these rats was devoid of 
cellular infiltrates (Fig. 1C).
The effect of the combined treatment with RBV+TR 
on microglial activation in EAE rats
An  ED1  microglial  marker  was  used  to  evalu-
ate microglia reactivity in the EAE-untreated and 
RBV+TR-treated rats. In the EAE-rats microglial 
cells  were  retracted  and  exhibited  an  amoeboid 
shape throughout the white matter of the lumbar 
spinal  cord,  suggestive  of  a  macrophage-like  cell 
type (Fig. 2A and c, insert). In the RBV+TR-treated 
rats, microglia exhibited a bushy morphology with 
short and thick processes (Fig. 2B and d, insert), 
fig. 2. ED1 immunostaining of lumbar spinal cord sections of EAE- and RBV+TR- animals. (A) In EAE rats, a huge number of micro-
glial cells with a morphology similar to macrophages (c, arrows, insert) were seen. In RBV+TR-treated rats a paucity of bushy microglial 
cells resembling resting microglia were noticed (b, d, arrows, insert). Gray matter (gm) and white matter (wm). Bars a, b: 400 µm; c, 
d: 100 µm. NuCLEOSIDE ANALOGuES AND GLIOSIS 847
displaying  a  less  activated  state  compared  to  the 
amoeboid microglia in the EAE rats. Quantitative 
studies of the microglial cell reactivity in the lum-
bar spinal cord of both groups of animals are pre-
sented in Table 2. 
The effect of the combined treatment with RBV+TR 
on astroglial reactions in EAE rats
We used glial fibrillary acidic protein (GFAP) and 
vimentin to determine astrocyte reactivity after 15 
fig. 3. GFAP and Vimentin immunostaining of lumbar spinal cord sections of EAE- and RBV+TR- animals. GFAP+ astrocytes of similar 
morphology were spread throughout the white matter of EAE rats (a) and RBV+TR-rats (d). In the gray matter of EAE-rats strong 
GFAP immunoreactivity was noticed, indicating astrocyte activation (b, c), whereas in RBV+TR-treated rats normal astroglial cells 
with small cell bodies and thin processes were observed (e, f). Vimentin+ astrocytes in EAE-rats formed a dense mesh of vimentin+ 
elongated astrocytes with small cell bodies and thin processes (g, h, arrows). In the white matter of RBV+TR-treated rats, vimentin im-
munoreactivity was minimal (i), except in the close vicinity of the perivascular space in the ventral columns of the white matter where 
vimentin+ astrocytes were clustered around the blood vessels (i, J, arrows). Bars a-J: 50 µm.848 DANIJELA SAVIĆ ET AL.
days of treatment in the white and gray matter of 
the lumbar spinal cord sections of the EAE-untreat-
ed and RBV+TR-treated rats. In the white matter of 
both groups, we detected the same level of GFAP 
immunoreactivity (Fig. 3A and D, Table 2). In the 
gray matter of the EAE rats, increased GFAP immu-
noreactivity characterized by astrocytes with swol-
len cell bodies and thick processes was seen (Fig. 
3B and c, Table 2). Conversely, in the gray matter of 
the RBV+TR-treated rats a reduction of GFAP im-
munoreactivity was observed; these astrocytes had 
small cell bodies and thin processes (Fig. 3E and f, 
Table 2). 
In addition, vimentin immunohistochemistry of 
the lumbar spinal cord sections demonstrated mini-
mal and moderate reactivity in the gray matter of the 
RBV+TR-treated and EAE-rats, respectively (Table 
2). Analysis of vimentin staining in the white matter 
of the EAE-rats revealed a strong immunoreactivity 
and a dense mesh of vimentin+ astrocytes that were 
elongated, with small cell bodies and thin processes 
(Fig. 3G and H, Table 2). Conversely, vimentin im-
munoreactivity in the white matter of the RBV+TR- 
treated rats was minimal (Table 2), except in the close 
vicinity of perivascular space in the ventral columns 
of white matter where an increased number of vi-
mentin+ astrocytes was detected (Fig. 3I and J). 
DISCuSSION
In this study we have shown that combined treat-
ment with ribavirin (RBV) and tiazofurin (TR) re-
duced the number and modulated the morphology 
of glial cells in established EAE in DA rats. Namely, 
combined treatment of EAE animals with RBV+TR 
switched the morphology of activated microglia into 
a less activated phenotype and suppressed reactive 
astrogliosis at the end of the treatment period.
Since  previously  we  confirmed  that  the  co-
administration of RBV and TR has a more potent 
effect in attenuating the clinical signs of EAE than 
each drug given individually (Stojkov et al., 2006), 
in this study we used a combined therapeutic ap-
proach as well. Consistent with our prior findings 
(Stojkov  et  al.,  2008),  combined  RBV+TR  treat-
ment significantly suppressed the development of 
EAE in terms of reducing disease severity, mono-
nuclear cell infiltration and demyelination. Consid-
ering that both of these nucleoside analogues could 
readily pass BBB (Colombo et al., 2011; Janac et al., 
Table 1. The effect of RBV+TR treatment on the parameters of disease severity.
EAE RBV+TR
№ of animals 16 16
mean clinical score per treatment day 1.68 ± 0.12 0.93 ± 0.17**
Mean maximal severity score 2.88 ± 0.10 2.13 ± 0.18**
Duration of paralysis 2.50 ± 0.43 0.50 ± 0.22**
Parameters of disease severity were evaluated as described in Materials and methods. Data are presented as mean ±SEM. *P < 0.05. ;**P 
< 0.001 vs. EAE-rats that were used as controls. 
Table 2. Degree of immunoreactivity for microglial cells (ED1), mature (GFAP) and immature (Vimentin) astrocytes in the EAE- and 
RBV+TR-groups 
Lumbar region of spinal cord Groups ED1 GFAP Vimentin
white matter
EAE  +++ ++ +++
RBV+TR + ++ +
gray matter
EAE  ++ +++ +
RBV+TR 0 + +
(0 = none, + minimal, ++ moderate, and +++ strong reactivity). Results are based on evaluation of lumbar spinal cord region of 3 – 4 
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2004), in this study we addressed the question of 
the impact of RBV and TR on the CNS and glial 
cells in particular. Microglial cells are crucial for the 
progress of MS and EAE since the activated form 
acquires the functional and morphological features 
of macrophages (Raivich and Banati, 2004). Acti-
vated microglia have the task of alerting nearby cells 
to possible threat and to provide for neuronal sur-
vival. On the other hand, during the chronic neu-
roinflammation that is a hallmark of MS and EAE, 
prolonged or excessive activation of microglial cells 
occurs and induces a potentially neurotoxic effect 
(Block et al., 2007). Thus, the prevalence of activat-
ed round-shaped macrophage-like microglial cells 
that we detected in the vicinity of the demyelinating 
areas in EAE animals can be considered as detri-
mental. Conversely, the less activated intermediate 
type of microglia that we observed in the RBV+TR-
treated animals may have a beneficial role. 
Activated microglial cells interact with another 
glial cell type, astrocytes, and trigger the process of 
reactive astrogliosis (Glass et al., 2010). MS lesions 
are characterized by an accumulation of hypertroph-
ic reactive astroglia that show strong GFAP, nestin 
and  vimentin  immunoreactivity  (Voskuhl  et  al., 
2009), similar to those observed in this study. Exist-
ing data indicate a dual role of astrocytes in MS and 
EAE development. Thus, reactive astrocytes have in 
some cases been proposed as potential mediators in 
the effector phase of EAE (Girvin et al., 2002) and as 
a source of proinflammatory cytokines (Nair et al., 
2008). On the other hand, the loss of scar-forming 
reactive astrocytes or interruption of their barrier 
functions  may  exacerbate  the  CNS  pathology  oc-
curring in diseases like MS and EAE (Voskuhl et al., 
2009). In the present study, the gray matter astroglia 
of EAE animals showed prominent hypertrophy and 
was correlated with massive peripheral cell infiltra-
tion. Wu et al. (2008) reported pronounced gray mat-
ter astrocyte activation in the presence of apoptotic 
oligodendrocyte processes in chronic EAE. In addi-
tion, neuronal death and gray matter atrophy was 
documented in mice with EAE (MacKenzie-Graham 
et al., 2006). Therefore, suppression of gray matter 
astrogliosis by RBV+TR treatment could indicate a 
reduction in neuronal or oligodendrocyte apoptosis. 
Astrogliosis is also characterized by the rapid syn-
thesis of two other intermediate filaments (vimentin 
and/or  nestin)  (Williams  et  al.,  2007).  Vimentin-
bearing astrocytes of the adult CNS have a mixed 
composition of cytoskeletal intermediate filaments 
that are positive for both GFAP and vimentin (Ob-
linger et al., 1993). Therefore, the attained stronger 
immunoreactivity to vimentin in the white matter of 
EAE animals compared to RBV+TR-treated animals 
was expected. However, it appears that combination 
therapy did not affect vimentin-positive astroglio-
sis adjacent to the perivascular space in the ventral 
columns  of  white  matter.  This  selective  action  of 
combination therapy could be beneficial since it was 
shown that reactive astrocytes might form scar-like 
perivascular barriers that limit the influx of immune 
and inflammatory leukocytes into CNS parenchyma 
(Voskuhl et al., 2009).
The possible mechanism of RBV and TR action 
on activated glial cells could be via the inhibition of 
IMPDH, the rate-limiting enzyme of de novo GTP 
biosynthesis. Through the inhibition of IMPDH II 
isoform, they exert antiproliferative action on rapidly 
dividing cells (Weber, 2005). Since this pathway is es-
sential for normal, as well as mitogenic functions of 
all cells, inhibition of IMDH II probably represents 
the main mechanism of RBV and TR deactivation 
and antiproliferative actions on activated microglia 
and reactive astrogliosis. 
To summarize, although it is well documented 
that RBV and TR suppress EAE acting outside the 
CNS  (Stosic-Grujicic  et  al.,  2002;  Lavrnja  et  al., 
2008; Stojkov et al., 2008), the results presented in 
this study clearly indicate that RBV and TR could be 
neuroprotective through the modulation of glial cell 
response during EAE. Therefore, the combined ad-
ministration of RBV and TR could be a promising 
therapeutic option against neurological disorders ag-
gravated by excessive microglial activation and reac-
tive astrogliosis. 
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